Jennifer Atkins
Thursday, January 14, 2016
FDA rejects BioMarin's muscle-wasting disorder drug
Jan 14 (Reuters) - BioMarin Pharmaceutical Inc said on Thursday the U.S. Food and Drug Administration had rejected its drug to treat a rare muscle-wasting disorder.
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment